Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 26, 2023

Details for Patent: 6,268,343

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 6,268,343 protect, and when does it expire?

Patent 6,268,343 protects SAXENDA and VICTOZA and is included in two NDAs.

Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-nine patent family members in twenty-three countries.

Summary for Patent: 6,268,343
Title: Derivatives of GLP-1 analogs
Abstract:The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.
Inventor(s): Knudsen; Liselotte Bjerre (Valby, DK), Huusfeldt; Per Olaf (K.o slashed.benhavn K, DK), Nielsen; Per Franklin (V.ae butted.rl.o slashed.se, DK), Kaarsholm; Niels C. (Vanl.o slashed.se, DK), Olsen; Helle Birk (Aller.o slashed.d, DK), Bj.o slashed.rn; S.o slashed.ren Erik (Lyngby, DK), Pedersen; Freddy Zimmerdahl (V.ae butted.rl.o slashed.se, DK), Madsen; Kjeld (V.ae butted.rl.o slashed.se, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:09/258,750
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,268,343
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,268,343

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novo Nordisk Inc VICTOZA liraglutide recombinant SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,268,343

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark0931/96Aug 30, 1996
Denmark1259/96Nov 08, 1996
Denmark1470/96Dec 20, 1996

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.